Frontlight ResearchEarly access
CompletedPhase 2
Suvorexant as an Adjunct to Buprenorphine in Persons Who Use Fentanyl
Key facts
- Who runs it
- Johns Hopkins University
- Where
- Baltimore, United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 76 people enrolled
- Started
- 30 Mar 2022
- Ended
- 3 Aug 2026
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Suvorexant
- Placebo
- Record updated
- 10 August 2026
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Aged 18-65
- Meets DSM-5 criteria for opioid use disorder (OUD) with evidence of physical dependence on opioids
- Provides a urine sample that tests positive for fentanyl and/or fentanyl analogues
- Interest in being maintained on buprenorphine for OUD
- Plans to reside in current area for study period
- Achieving a study maintenance dose of \>=8mg sublingual buprenorphine/naloxone
- Willing to comply with study protocol
- Have no clinically significant chronic medical or surgical disorders or conditions that are judged by the investigators to prevent participation
Who cannot take part
- Medically contraindicated for buprenorphine, extended-release (XR)-buprenorphine (Sublocade), or suvorexant (as per medication labels)
- Current benzodiazepine or other prescribed medication for the indication of insomnia
- Severe Diagnostic and Statistical Manual (DSM)-5 alcohol or benzodiazepine use disorder or evidence of alcohol/benzodiazepine physical dependence
- Have a known allergy to the study medications
- Current narcolepsy, restless leg syndrome or sleep paralysis
- Past year clinically-significant psychiatric condition judged to interfere with study participation
- Severe hepatic or renal impairment; aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \>3x upper limit of normal (ULN); Total bilirubin \>2x ULN; Creatinine \>1.5x ULN
- Pregnant or breast feeding
- Past 30-day prescribed use of suvorexant for the indication of insomnia
- Urine sample testing positive for benzodiazepine at screening and admission to residential treatment
- High risk for current sleep apnea
- Current (past 30-day) suicidal behaviors
- Lack of access to stable housing (necessary for electronic pill dispenser charging)
- Have circumstances that would interfere with study participation (e.g., impending jail)
Where in United States
- Johns Hopkins Bayview Medical CenterBaltimore, United States
About the trial
What the trial wants to find out
This is a 4-week, randomized-controlled trial of suvorexant vs placebo in persons with opioid use disorder who have recent fentanyl exposure. Participants will first undergo a 5-day residential phase wherein participants are stabilized on sublingual buprenorphine/naloxone, followed by a 3-week outpatient phase wherein participants are maintained on sublingual buprenorphine/naloxone and transitioned to extended-release buprenorphine).
The 2 groups in the trial
- SuvorexantTreatment being tested
Nightly dosing of suvorexant
- PlaceboPlacebo, for comparison
Nightly dosing of placebo
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Suvorexant as an Adjunct to Buprenorphine Induction and Maintenance in Persons Who Use Fentanyl
- Record updated
- 10 August 2026